Christoph Spiess

Christoph Spiess

Auto-generated profile, based on publicly available information

Christoph Spiess

Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1999 in Cell
Verified
Journal Article
Closed access
CSChristoph Spiess
Christoph Spiess
ABAlexandra Beil
Alexandra Beil
MEMichael Ehrmann
Michael Ehrmann

1 October 2015 in Molecular Immunology
Verified
Journal Article
Open access
CSChristoph Spiess
Christoph Spiess
QZQianting Zhai
Qianting Zhai
PCPaul J. Carter
Paul J. Carter
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab(®), anti-EpCAM×anti-CD3) and blinatumomab (Blincyto(®), anti-CD19×anti-CD3) are approved for therapy, and >30 additional bispecific antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. These formats vary in many ways including their molecular weight, number of antigen-binding sites, spatial relationship between different binding sites, valency for each antigen, ability to support secondary immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.

17 September 2006 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
STStephen Tam
Stephen Tam
RGRon Geller
Ron Geller
CSChristoph Spiess
Christoph Spiess
JFjudith Frydman
judith Frydman

1 March 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MLMegan Lo
Megan Lo
HKHok Seon Kim
Hok Seon Kim
RTRaymond K. Tong
Raymond K. Tong
TBTravis W. Bainbridge
Travis W. Bainbridge
JVJean-Michel Vernes
Jean-Michel Vernes
JEJames A. Ernst
James A. Ernst
The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a therapeutic context, however, the cytotoxic effector function of an antibody is often not desirable and can create safety liabilities by activating native host immune defenses against cells expressing the receptor antigens. Several amino acid changes in the Fc region have been reported to silence or reduce the effector function of antibodies. These earlier studies focused primarily on the interaction of human antibodies with human Fc-γ receptors, and it remains largely unknown how such changes to Fc might translate to the context of a murine antibody. We demonstrate that the commonly used N297G (NG) and D265A, N297G (DANG) variants that are efficacious in attenuating effector function in primates retain potent complement activation capacity in mice, leading to safety liabilities in murine studies. In contrast, we found an L234A, L235A, P329G (LALA-PG) variant that eliminates complement binding and fixation as well as Fc-γ-dependent, antibody-dependent, cell-mediated cytotoxity in both murine IgG2a and human IgG1. These LALA-PG substitutions allow a more accurate translation of results generated with an “effectorless” antibody between mice and primates. Further, we show that both human and murine antibodies containing the LALA-PG variant have typical pharmacokinetics in rodents and retain thermostability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to generating highly effector-attenuated bispecific antibodies for preclinical studies.

1 November 2004 in Trends in Cell Biology
Verified
Journal Article
Closed access
CSChristoph Spiess
Christoph Spiess
AMAnne Meyer
Anne Meyer
SRStefanie Reissmann
Stefanie Reissmann
JFjudith Frydman
judith Frydman

15 November 2009 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
STStephen Tam
Stephen Tam
CSChristoph Spiess
Christoph Spiess
WAWilliam Auyeung
William Auyeung
LJLukasz Joachimiak
Lukasz Joachimiak
BCBryan Chen
Bryan Chen
JFJudith Frydman
Judith Frydman
The eukaryotic group II chaperonin TRiC can block polyQ tract aggregation, present in proteins such as Htt. Here the TRiC-Htt interaction is examined using in vitro and in vivo experiments, revealing that TRiC does not physically block the polyQ tract, but rather sequesters a short N-terminal sequence that promotes the amyloidogenic conformation. Aggregation of proteins containing polyglutamine (polyQ) expansions characterizes many neurodegenerative disorders, including Huntington's disease. Molecular chaperones modulate the aggregation and toxicity of the huntingtin (Htt) protein by an ill-defined mechanism. Here we determine how the chaperonin TRiC suppresses Htt aggregation. Unexpectedly, TRiC does not physically block the polyQ tract itself, but rather sequesters a short Htt sequence element, N-terminal to the polyQ tract, that promotes the amyloidogenic conformation. The residues of this element essential for rapid Htt aggregation are directly bound by TRiC. Our findings illustrate how molecular chaperones, which recognize hydrophobic determinants, can prevent aggregation of polar polyQ tracts associated with neurodegenerative diseases. The observation that short endogenous sequence elements can accelerate the switch of polyQ tracts to an amyloidogenic conformation provides a novel target for therapeutic strategies.